Scilex Holding Company (Nasdaq: SCLX) will present a post-hoc analysis of the C.L.E.A.R. trial at the 27th Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025. The analysis focuses on the clinical meaningfulness of the safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP). The poster presentation, authored by a team including Miller, Knezevic, and Lissin, will be accessible throughout the meeting, on the conference app, and published in the •Pain Physician• journal.
This presentation is important because it provides further insights into the potential of SP-102 (SEMDEXA™) as a treatment for LRP, commonly known as sciatica. A deeper understanding of the clinical meaningfulness of the trial data is crucial for physicians considering this treatment option for their patients. Dissemination through a peer-reviewed journal like •Pain Physician• lends further credibility to the findings and increases its reach within the medical community. This wider dissemination could accelerate adoption if the data strongly supports SP-102’s efficacy and safety profile.
The post-hoc analysis of the C.L.E.A.R. trial interprets the clinical meaningfulness of both safety and efficacy outcomes for SP-102 in LRP treatment. The presentation format, a scientific poster at a prominent pain management conference, allows for efficient communication of key findings to a specialized audience. Publication in the •Pain Physician• journal ensures wider access to the data for researchers and clinicians.
This presentation represents a significant step for Scilex in building a stronger evidence base for SP-102. Positive findings could influence treatment guidelines and encourage broader adoption by physicians, ultimately benefiting patients seeking relief from sciatica. The increased visibility could also attract further investment and partnerships, accelerating Scilex’s growth and positioning them as a leader in non-opioid pain management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
